LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

Search

Novartis AG

Fermé

126.26 -0.21

Résumé

Variation du prix de l'action

24h

Actuel

Min

125.94

Max

126.93

Chiffres clés

By Trading Economics

Revenu

418M

4B

Ventes

660M

14B

P/E

Moyenne du Secteur

18.227

35.724

BPA

2.42

Rendement du dividende

3.15

Marge bénéficiaire

28.18

Employés

75,883

EBITDA

-5.8B

4.9M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

-6.32% downside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.15%

3.09%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

3B

242B

Ouverture précédente

126.47

Clôture précédente

126.26

Score Technique

By Trading Central

Confiance

Bearish Evidence

Novartis AG Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

7 août 2025, 05:47 UTC

Acquisitions, Fusions, Rachats

Novartis Makes Takeover Approach for Avidity Biosciences, FT Says, Citing Sources

17 juil. 2025, 14:26 UTC

Résultats

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- 2nd Update

17 juil. 2025, 06:49 UTC

Résultats

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- Update

17 juil. 2025, 05:41 UTC

Résultats

Novartis Lifts Profit Outlook After Growth in Sales, Earnings

11 août 2025, 11:16 UTC

Résultats

Rheinmetall, Ørsted, Novartis: Global Stocks in Focus -- WSJ

8 août 2025, 11:26 UTC

Market Talk

Novartis Is Getting Closer to Midterm Targets -- Market Talk

8 août 2025, 11:07 UTC

Market Talk
Acquisitions, Fusions, Rachats

Novartis Has Room to Accelerate Dealmaking -- Market Talk

8 août 2025, 10:51 UTC

Market Talk
Acquisitions, Fusions, Rachats

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

5 août 2025, 10:40 UTC

Market Talk

Roche, Novartis Face Limited Tariff Headwinds for Now -- Market Talk

17 juil. 2025, 11:36 UTC

Market Talk

Novartis CEO Urges Europe to Reform Drug-Pricing System -- Market Talk

17 juil. 2025, 11:26 UTC

Market Talk

Novartis CEO Confident on Midterm Plan to Mitigate U.S. Tariff Hit -- Market Talk

17 juil. 2025, 07:14 UTC

Market Talk

Retirement of Well-Regarded Executive a Loss for Novartis -- Market Talk

17 juil. 2025, 07:02 UTC

Market Talk
Résultats

Novartis's Results Look Impressive -- Market Talk

17 juil. 2025, 05:09 UTC

Résultats

Novartis 2Q Sales Grew 11% at Constant Currency

17 juil. 2025, 05:08 UTC

Résultats

Novartis: Kirsch Will Continue as CFO, Member of Executive Committee Until March 2026

17 juil. 2025, 05:06 UTC

Résultats

Novartis: Mehta's Appointment Is Effective March 2026

17 juil. 2025, 05:05 UTC

Résultats

Novartis: Harry Kirsch Retires After 22 Years With Company

17 juil. 2025, 05:05 UTC

Résultats

Novartis Names Mukul Mehta as CFO

17 juil. 2025, 05:04 UTC

Résultats

Analysts Saw Novartis 2Q Net Profit at $3.815B

17 juil. 2025, 05:04 UTC

Résultats

Analysts Saw Novartis 2Q Core Operating Profit at $5.75B

17 juil. 2025, 05:04 UTC

Résultats

Analysts Saw Novartis 2Q Sales at $14.17B

17 juil. 2025, 05:04 UTC

Résultats

Novartis 2Q Core Operating Profit $5.925B

17 juil. 2025, 05:04 UTC

Résultats

Novartis 2Q Oper Pft $4.86B

17 juil. 2025, 05:03 UTC

Résultats

Novartis 2Q Sales $14.05B

17 juil. 2025, 05:01 UTC

Résultats

Novartis: Buyback to Be Completed by End of 2027

17 juil. 2025, 05:01 UTC

Résultats

Novartis Starting Buyback of Up to $10B

17 juil. 2025, 05:01 UTC

Résultats

Novartis Backs 2025 Sales View

17 juil. 2025, 05:01 UTC

Résultats

Novartis Had Guided for Low Double-Digit Growth in Core Operating Profit at Constant Currency

17 juil. 2025, 05:01 UTC

Résultats

Novartis Expects 2025 Core Operating Profit to Grow by Low Teens at Constant Currency

17 juil. 2025, 05:00 UTC

Résultats

Novartis Raises 2025 Earnings View

Comparaison

Variation de prix

Novartis AG prévision

Objectif de Prix

By TipRanks

-6.32% baisse

Prévisions sur 12 Mois

Moyen 118.87 USD  -6.32%

Haut 138.489 USD

Bas 100 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

5 ratings

1

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

N/A / 112.63Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Strong Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.